<DOC>
	<DOCNO>NCT00003707</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase I trial study effectiveness combine R115777 gemcitabine treat patient advanced cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose dose limit toxicity tipifarnib combination gemcitabine patient advance cancer . - Investigate potential pharmacokinetic interaction tipifarnib gemcitabine patient . - Determine efficacy regimen patient measurable evaluable disease . - Evaluate quality life patient . OUTLINE : This dose-escalation study tipifarnib . Patients receive gemcitabine IV 30 minute day 1 , 8 , 15 oral tipifarnib every 12 hour begin day 2 . Treatment continue every 4 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos tipifarnib maximum tolerate dose ( MTD ) reach . The MTD define dose few one third patient experience dose limit toxicity . Quality life assess treatment , day 22 course , end treatment . PROJECTED ACCRUAL : A maximum 40 patient accrue study .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologically proven advanced cancer curative therapy exist PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 Hemoglobin great 9 g/dL Hepatic : Bilirubin normal SGOT SGPT great 2 time upper limit normal ( ULN ) ( great 5 time ULN liver metastasis present ) Renal : Creatinine normal Other : Unassisted oral enteral intake sufficient maintain reasonable state nutrition No concurrent medical condition likely interfere study participation No active visual disturbance require intervention beyond corrective lens Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior bone marrow transplantation No concurrent immunotherapy Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) No prior high dose chemotherapy bone marrow stem cell rescue No concurrent chemotherapy Endocrine therapy : No concurrent hormone therapy ( except megestrol acetate ) Radiotherapy : At least 4 week since prior radiotherapy No prior radiotherapy 25 % bone marrow No concurrent radiotherapy ( except palliative radiotherapy within first 28 day study ) Surgery : Not specify Other : At least 30 day since prior investigational therapy No concurrent investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>